Enhabit, Inc. (NYSE:EHAB) Short Interest Down 5.4% in December

Enhabit, Inc. (NYSE:EHAB) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 1,220,000 shares, a drop of 5.4% from the December 15th total of 1,290,000 shares. Based on an average daily volume of 375,300 shares, the short-interest ratio is presently 3.3 days. Approximately 2.8% of the company’s shares are sold short.

Enhabit Stock Up 0.2 %

Shares of EHAB stock opened at $7.99 on Monday. The firm’s fifty day moving average price is $7.83 and its two-hundred day moving average price is $8.11. Enhabit has a 1 year low of $6.85 and a 1 year high of $11.74. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $401.49 million, a P/E ratio of -3.44 and a beta of 1.82.

Enhabit (NYSE:EHAB) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $253.60 million for the quarter, compared to analyst estimates of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same period last year, the company posted $0.03 earnings per share. On average, equities analysts predict that Enhabit will post 0.22 EPS for the current fiscal year.

Insider Transactions at Enhabit

In other Enhabit news, Director Stuart M. Mcguigan purchased 15,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were bought at an average price of $8.81 per share, with a total value of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares in the company, valued at $412,396.10. This trade represents a 47.15 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Bolton acquired 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $8.69 per share, with a total value of $34,760.00. Following the completion of the transaction, the director now directly owns 98,144 shares in the company, valued at $852,871.36. This trade represents a 4.25 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On Enhabit

A number of institutional investors have recently added to or reduced their stakes in EHAB. JPMorgan Chase & Co. grew its position in shares of Enhabit by 37.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 305,245 shares of the company’s stock valued at $2,411,000 after acquiring an additional 83,707 shares during the period. Franklin Resources Inc. lifted its stake in Enhabit by 19.6% in the 3rd quarter. Franklin Resources Inc. now owns 32,382 shares of the company’s stock valued at $256,000 after purchasing an additional 5,317 shares during the last quarter. Geode Capital Management LLC grew its holdings in Enhabit by 0.9% during the third quarter. Geode Capital Management LLC now owns 1,137,458 shares of the company’s stock worth $8,987,000 after purchasing an additional 10,538 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Enhabit in the third quarter valued at approximately $450,000. Finally, XTX Topco Ltd bought a new position in shares of Enhabit during the 3rd quarter worth approximately $123,000.

Analyst Ratings Changes

Several research firms recently commented on EHAB. Leerink Partners reaffirmed a “market perform” rating and issued a $8.00 price objective (down from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and boosted their price target for the company from $8.25 to $9.50 in a report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.75.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.